BioWorld

May 12, 2004

With SPA Agreement, Xenova Plans Two TransMID Phase IIIs

Xenova Group plc immediately expects to commence the first of two planned Phase III trials for TransMID, a candidate for brain cancer. (BioWorld Today) Read More

Illumina Files $65M Shelf, Raises $31M In Direct Sale

Mutation, Rash Clues May Sharpen Focus For EGFR Cancer Therapies

Nearing Human Trials, Acuity's Approach Attracting Investors

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Heartbeam wins appeal, gains FDA clearance

BioWorld MedTech

Management is beaming with delight at Heartbeam Inc. as the company's appeal strategy paid off with U.S. FDA clearance for its synthetic 12-lead electrocardiogram...